Novo Nordisk aligns Ozempic pricing with generics in Canada as Apotex begins shipping

Novo Nordisk has cut what uninsured Canadians pay for brand-name Ozempic through a savings card, timing the move to Apotex's first shipments of generic semaglutide and wider distribution from Dr. Reddy's ^[1]. The savings card, first launched in August 2026, aligns Ozempic's price with generic pricing for patients without insurance, and is offered through Rexall pharmacies in every province and territory except Quebec ^[1]. Novo Nordisk is also running consumer ads in Canada that urge patients to ask their pharmacist for the brand-name product rather than switching to a generic ^[1].

The pricing fight follows a series of Canadian regulatory approvals. Health Canada authorized Dr. Reddy's generic semaglutide on April 28, and BMJ reported that Canada became only the second country in the world to approve a generic version of the drug ^[1]. Apotex has since offered what the tracking site GLP1Prices describes as full SKU parity with Ozempic, meaning it matches the branded drug's available doses and forms, while eight more generic semaglutide submissions remain under Health Canada review ^[1]. Three of nine generic semaglutide products have been approved by Health Canada as of the most recent count ^[1].

Canada's drug-pricing system is also set to squeeze prices further as more generics arrive. Under the pan-Canadian Pharmaceutical Alliance's tiered structure, a first generic entrant is priced at 75 to 85 percent of the brand price, but once three or more generics reach the market, that price is expected to fall to 35 percent of brand ^[1]. Health plan sponsors are described as bracing for a 65 percent list-price cut once a third generic semaglutide launches, with Sandoz reportedly targeting a Q3 2026 entry ^[1]. How this unfolds in Canada is being watched partly because of how the branded product lost patent protection there: Novo Nordisk stopped paying a roughly $250 annual patent maintenance fee in 2018, a lapse that patent expert Tahir Amin of I-MAK told the BBC meant the company could have extended its Canadian Ozempic patent until 2028 but did not renew it ^[1].

Novo Nordisk's financial guidance reflects the pressure. The company has forecast a 5 to 13 percent decline in 2026 sales as generic semaglutide reaches Canadian pharmacies, even as it pushes its oral Wegovy pill, which CEO Mike Doustdar has called a "must-win" battle for the year ^[1]. Eli Lilly, by contrast, has projected $80 billion to $83 billion in 2026 revenue and reported $9.94 billion in second-quarter Mounjaro sales, while flagging supply constraints among Canadian generic tirzepatide entrants ^[1]. Sandoz has estimated its proposed generic tirzepatide could be priced at $200 to $400 a month ^[1].

Why it matters for patients

This is happening in Canada, not the United States, so the savings card and generic Ozempic pricing described here do not apply to US patients buying Ozempic, Wegovy, or Rybelsus today ^[1]. But the situation offers an early look at how an originator company might respond if and when semaglutide loses patent protection in the US market, since Novo Nordisk is choosing to compete on price and brand loyalty rather than simply losing volume to generics ^[1]. US patients should also be aware that Health Canada has separately warned about counterfeit and unauthorized Ozempic and Mounjaro products being sold by unlicensed retailers and online sellers, a caution that applies broadly to anyone considering non-pharmacy sources of these drugs ^[1].

What happens next

Eight additional generic semaglutide submissions remain under Health Canada review, and their approval could push the market past the three-generic threshold that triggers a 65 percent list-price cut under Canada's pricing rules ^[1]. Sandoz has said it is targeting a third-quarter 2026 entry for a generic version, which would be a key marker to watch ^[1]. Novo Nordisk's oral Wegovy launch, already approved in the US as of December 2025, is expected to be a major part of the company's competitive response through the rest of 2026 ^[1].